related to higher cortisol metabolite production at 12 months, independent of demographics and breastfeeding.
Conclusions: Greatest weight loss in the postpartum year was associated with lower conversion of cortisone to cortisol and lower conversion of cortisol to its metabolites, supporting previous work that demonstrates the facilitative role of lower 5α-reductase and 11β-HSD-1 in weight loss. Greater depression symptoms were associated with higher cortisol metabolite production rates. Whilst weight and mental health are both associated with dysregulation of the HPA axis, there may be different pathways towards depressed and obese phenotypes in healthy postpartum samples.
Background
Maternal postpartum weight trajectories are important factors in immediate and long-term maternal physical and mental health. Two thirds of women retain weight after pregnancy 1 .
The risk of depression and anxiety is significantly higher in women who retain two or more BMI units at 6 months postpartum 2 . Women who gain excess weight during pregnancy are 2.15 times as likely to be overweight and 4.49 times as likely to be obese two decades later 3 .
Unsuccessful postpartum weight loss is a risk factor for long-term obesity 1, 4 and postnatal adiposity tends to have centralised distribution thus increasing risk of disease 5 . There is considerable variability of postpartum weight change (e.g. mean (±SD) of +1.1kg (±7.6kg) at 14 months postpartum 6 ) with lower weight retention predicted by married status, lower gestational weight gain and longer breastfeeding 6 . Maternal depressed mood has also been This article is protected by copyright. All rights reserved.
associated with poorer postpartum weight loss trajectories 2 and obesity is a risk factor for postnatal depression 7 .
Dysregulation of the Hypothalamic-Pituitary-Adrenal (HPA) axis is common in obesity and mental health disorders, indicating a possible mechanistic link 8 . Women with higher prenatal depression scores have been shown to have higher salivary cortisol 9 and maternal distress in pregnancy is related to plasma cortisol levels 10 . However, some studies show weak associations [11] [12] . This may be because relationships between pregnancy distress and circulating cortisol may not necessarily be linear or may vary with gestation 12 . For example, in one study of severely obese pregnant women, both very high and very low maternally reported anxiety was related to low serum cortisol levels 13 . Furthermore, higher serum cortisol levels in late pregnancy predicts greater postpartum weight retention in severely obese women 13 . However, serum cortisol level does not mediate between mental health and postpartum weight retention 13 . In obese individuals, circulatory cortisol concentrations are often normal or low 14 due to enhanced excretion accompanied by increased metabolic clearance 15 . Therefore, investigation of the role of cortisol metabolism, rather than level, in postnatal mental health and weight loss/retention is warranted.
Little is known about the metabolic underpinnings of postpartum weight change or postpartum mental health. Steroid hormone metabolism has been linked to insulin resistance, obesity and the metabolic syndrome 16 . Longitudinal changes in glucocorticoid metabolism are associated with the development of adverse metabolic phenotypes, with higher total glucocorticoid production linked to increased BMI and abnormal glucose tolerance 17 .
Examination of the activity of the enzymes 11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD-1, which converts inactive cortisone to cortisol), 11ß-hydroxysteroid dehydrogenase
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type 2 (11ß-HSD-2, which converts cortisol to inactive cortisone) and 5α-reductase (which converts cortisol to its tetrahydrometabolites) has established their role in the development and maintenance of metabolic disease 17 . 11ß-HSD-1 is highly expressed in adipose tissue from obese individuals and inhibition of 11ß-HSD-1 results in weight loss and improvements in glycaemic control [18] [19] [20] [21] . 11ß-HSD-2 is expressed in the kidney and has a role in controlling blood pressure via its blocking of cortisol's activation of the mineralocorticoid receptor.
There is a positive relationship between 5α-reductase and markers of insulin resistance 22 .
In addition to its role in metabolic disease, cortisol metabolism is implicated in a number of mental health problems, particularly depression, anxiety and psychosis [23] [24] [25] . 5α-reductase inhibitors have been associated with symptoms of depression 26 and depressed patients show lower 5α-reductase and 11ß-HSD-2 activity suggesting less clearance of cortisol 24 .
Pharmacological treatment of depression for 4 weeks results in increases in 5α-reductase activity to levels comparable to a non-depressed control group 24 .
Previously, we have described postpartum corticosteroid metabolism in this cohort of women 27 . 11β-HSD-1 and 11β-HSD-2 activity did not show significant changes with time.
5α-reductase activity was low in the immediate post-partum period, increased over the initial 3 months and then gradually stabilised, returning to levels comparable to a comparison female cohort who had not recently been pregnant. However, there has been no longitudinal assessment of the relationship between weight change and steroid metabolism postpartum.
Neither has the role of steroid metabolism in maternal postnatal depression been previously examined. Therefore, this exploratory study aimed to describe the maternal postpartum weight change trajectory and associated pattern of glucocorticoid metabolism in a sample of UK women across the first postnatal year; examine the concurrent relationships between
maternal glucocorticoid metabolism and maternal symptoms of postnatal depression; and examine the relationships between weight change and maternal glucocorticoid metabolism in the postpartum year independent of confounds of breastfeeding, demographics and maternal depression. We hypothesised that greater weight loss would be associated with lower 11β-HSD-1 and 5α-reductase activity, increased 11β-HSD-2 activity and with a reduced total F metabolite production rate. We hypothesised that higher depression scores would be associated with greater weight retention as well as lower 5α-reductase and 11β-HSD-2 activity. We also predicted that higher 11β-HSD-1 activity and total F metabolite production rate would be related to poorer mental health.
Method

Materials and Methods
The 
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Urinary steroid metabolite analysis
Spot urine samples were analysed; absolute corticosteroid concentrations were corrected per g of urinary creatinine to assess absolute production rates. Previous work has demonstrated that spot urine samples yield measures of corticosteroid activity that are very highly correlated with measures from 24 hour samples (r=.959) and thus spot urine samples accurately reflect daily corticosteroid activity 29 . Gas chromatography / mass spectroscopy (GC/MS) was used to analyse urinary corticosteroid metabolites as described elsewhere 16, 30 .
Solid-phase extraction was used to extract free and conjugated steroids. Steroids were enzymatically released from conjugation and then re-extracted. Methyloximetrimethylsilyethers (MO-TMS) were formed by adding internal standard (stigmasterol) prior to derivitization. The final derivative was dissolved in cyclohexane and transferred to a GC/MS autosampler vial. An Agilent 5973 instrument in selected-ion-monitoring (SIM) mode was used to run the samples.
The sum of total cortisol metabolites (THF (tetrahydrocortisol), THE (tetrahydrocortisone), 5α-THF, α-cortolone, cortisone (E), cortisol (F), β-cortolone, β-cortol, α-cortol) was used to measure cortisol secretion rate (total F metabolites). Here, the term total F metabolites means
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the total of measured metabolites, not the complete excretion of all metabolites. The ratio of tetrahydro-metabolites of cortisol (THF + 5αTHF) to those of cortisone (THE) was used to measure 11β-HSD-1 activity. The ratio of urinary cortisol (F) to cortisone (E) accurately reflects renal 11β-HSD-2 activity (with higher F/E ratios indicating decreased 11β-HSD-2 activity). The activity of 5α-reductase was inferred from measuring the ratio of 5αTHF/THF. small for gestational age were not eligible for participation. Two mothers were pregnant at the 12-month visit, so their data were removed from all analyses. Urine samples and sufficient data for calculation of BMI change was available for 49 of the women who gave consent to take part in the study.
Participants
Statistical approach
Statistical analysis was undertaken using IBM SPSS v22. Repeated Measures ANOVAs were used to examine changes across time in BMI, postnatal depression and cortisol metabolism.
Observed power was reported. Posthoc pairwise comparisons identified the source of significant effects. Maternal BMI change scores (ΔBMI) at each stage were calculated.
Positive ΔBMI implies reductions in BMI. For parsimony, total postpartum ΔBMI score was calculated from 1 week to 12-months postpartum and used in all analyses of relationships
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between weight change and cortisol metabolism. Pearson's correlation coefficients between demographics, breastfeeding duration, symptoms of depression and maternal steroid metabolism determined the necessity to control for these covariates in subsequent analyses.
Post hoc power estimates were calculated. Bonferroni corrections were not applied given their unnecessarily stringent effects because we did not want to increase the risk of type II error in this relatively small sample, given the exploratory nature of the work. Postnatal depression symptoms at 1, 6 and 12 months and overall ΔBMI across the postnatal year were then correlated with glucocorticoid metabolism at each data collection point, using one-tailed partial correlation analyses controlling for maternal age, education, income, smoking, alcohol consumption and total breastfeeding duration. Additionally, analysis of ΔBMI glucocorticoid metabolism relationships were adjusted for depression. Table 1 illustrates the descriptive and demographic information of participants providing weight and urine measures at each time point.
Results
Table 1 about here
The sample were affluent, well educated, relatively healthy weight, predominantly White British, with high initial breastfeeding rates and low levels of pregnancy smoking. 
BMI change across the postpartum year
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Maternal symptoms of postnatal depression across the postpartum year
Repeated Measures ANOVA demonstrated that there was no significant change in postnatal depression symptoms across the postnatal year although there was a trend towards fewer symptoms with time (Pillai's Trace F(2,47)=2.71, p<.077; observed power .51). Posthoc pairwise comparisons showed a significant decrease in postnatal depression symptoms between 1 month and 12 months only (p<.023) (see Figure 1b) . Table 3 illustrates the pattern of cortisol metabolism from pre-pregnancy to 1 year postpartum. Steroid metabolite analysis from some of these individuals have been reported
Maternal glucocorticoid metabolism across the postpartum year
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elsewhere in the context of infant growth and development across the first year of life 27 .
Presented in Table 3 (p<.0001) and at 1 month and all other time points (p<.0001). Activity was higher at 3 months than at 1 week and 1 month and lower than at 6 and 12 months (p<.05). There were no significant differences between 6 and 12-month 5α-reductase activity. Differences in 11β-HSD-1 were less profound but post hoc comparisons showed a significant difference in 11β-HSD-1 activity between 1 week and 1 month, and between 1 week and 6 months (p<.05).
11β-HSD-1 activity at 1 month was also lower than that at 3 and 6 months (p<.05). 11β-HSD-1 at 3 months was lower than at 6 months (p<.05). Finally, 11β-HSD-1 activity at 6 months was significantly higher than at 12 months (p<.05) (see Figure 1 c-f).
Figure 1 about here
To examine which variables were required as covariates in subsequent analyses, one tailed
Pearson's correlation coefficients between demographics, breastfeeding, symptoms of depression, postpartum ΔBMI and cortisol metabolism were calculated (Table 4) . 
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This article is protected by copyright. All rights reserved. To examine the relationships between symptoms of postnatal depression with cortisol metabolism, and BMI change with cortisol metabolism, a series of partial correlations coefficients were calculated controlling for covariates ( Table 5) . Correlations between BMI change and cortisol metabolism were additionally adjusted for symptoms of depression at 12 months.
Adjusted Relationships between symptoms of postnatal depression and maternal glucocorticoid metabolism across the postpartum year
After adjusting for demographics and breastfeeding, the pattern of relationships between symptoms of postnatal depression and concurrent cortisol metabolism remained the same:
women with poorer mental health at 12 months had greater concurrent total cortisol secretion rates. There were no other relationships between measures of depression and cortisol metabolism at any other time points.
Adjusted Relationships between ΔBMI and maternal glucocorticoid metabolism across the postpartum year 11ß-HSD activity
After adjusting for covariates, greater ΔBMI was associated with significantly lower 11β-HSD-1 activity at 1 week and 12 months postpartum. Women with greater 11ß-HSD-2 activity at 1 week showed more weight loss in the postpartum year.
5α-reductase activity
Adjusting for covariates removed the significance of 5α-reductase activity at one week and one month, and reduced the relationship between 6-month 5α-reductase activity and ΔBMI to a trend. Lower 5α-reductase activity at 3 months and 1 year remained significantly associated with greater postpartum ΔBMI.
Total F Metabolites
After adjusting for covariates, there were no significant associations between total F metabolites and ΔBMI.
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activity (at one week and 12 months) was associated with enhanced weight loss, which may reflect decreased adipocyte differentiation and lipid accumulation as a consequence of decreased tissue specific cortisol availability 33 . Although 11βHSD-2 is not thought to be expressed at significant levels in adipose tissue, the global increase in activity that we observed may also contribute to decreased tissue glucocorticoid availability. Only 11ßHSD-2 activity at 1 week was associated with greater weight loss in the postnatal year, suggesting that urinary measures of this enzyme are not key determinants of postnatal weight loss nor key correlates of postnatal depression in healthy participants.
Lower 5α-reductase activity at 3 and 12 months postpartum was associated with increased weight loss. There are 2 isoforms of 5α-reductase (type 1 and type 2) that have differential tissue specific expression profiles and both contribute to steroid hormone metabolism. 34 Cross-sectional studies have demonstrated the association between increased 5α-reductase activity and adverse metabolic phenotype 16, 17, 35 . This extends to simple obesity, non-alcoholic fatty liver disease and the adverse metabolic phenotype associated with polycystic ovary syndrome. Weight loss is associated with a reduction of 5α-reductase activity 22 . 5α-reductase clears glucocorticoids to their inactive dihydro-metabolites (subsequently converted to tetrahydro-metabolites by the action of 3α-hydroxysteroid dehydrogenase) and therefore limiting glucocorticoid availability to bind and activate the glucocorticoid receptor. In addition, they have a role in activating androgens, converting testosterone to the more potent androgen dihydrotestosterone. Lowering activity has the potential to decrease androgen availability whilst simultaneously reducing glucocorticoid clearance, and both androgens and glucocorticoids regulate fat mass. What remains unclear is whether changes in 5α-reductase reflect cause or consequence of changes in postpartum BMI; the associations that we have described cannot infer causality. Rodent models with genetic deletion of 5α-reductase type 1
have an adverse metabolic phenotype, largely confined to the liver without alteration in fat
This article is protected by copyright. All rights reserved. mass 36 . Clinical studies in patients have shown that non-selective 5α-reductase inhibition (type 1 and 2), but not exclusive type 2 inhibition, is associated with systemic and hepatic insulin resistance and with hepatic lipid accumulation 37 . Taken together, it seems likely that the changes that we have observed in 5α-reductase activity reflect a compensatory response such that with weight gain, glucocorticoid availability to bind and activate its receptor is limited. This may occur in response to the increased adrenal glucocorticoid output that is seen with increased weight 38 . As weight falls, adrenal glucocorticoid output falls and as a result there is no longer the need to repress local glucocorticoid availability and in parallel therefore, 5α-reductase activity decreases. Therefore, patients with the largest weight loss display greatest reduction in 5α-reductase activity.
Total glucocorticoid production was significantly correlated with depression symptoms at 12
months, but there were no relationships between postnatal depression at any other time point or any other measures of cortisol metabolism. However, 6% of the women in the sample had EPDS scores indicating probable major depression at 12 months and mean EPDS score was 5, comparable to other relatively mentally healthy UK postnatal samples 39 . Despite this, women with more depression symptoms at 12 months had greater total cortisol metabolite production, previously associated with greater BMI and abnormal glucose tolerance 17 . The causal nature and long term implications of this relationship is impossible to determine from our data, but are consistent with the suggestion that women with greater, and/or more persistent, symptoms of postnatal depression may be at greater risk for the development of metabolic disorders.
The clinical implications of these findings are limited at this stage given the healthy nature of our sample. However, for women with a problematic postnatal weight loss trajectory, selective 11β-HSD-1 inhibitors could be investigated as an adjunct to diet and lifestyle intervention to aid weight loss. Furthermore, examination of total glucocorticoid production
using spot urine samples has the potential to offer a more personalised approach to the evaluation of future metabolic and mental health risk.
In general, our findings regarding links between maternal postnatal mental health, weight retention and cortisol metabolism in this healthy sample show similarities to the patterns found in severely obese women, when serum cortisol levels were measured 13 ; mental health was related to cortisol level, cortisol level was related to postnatal weight retention but cortisol level did not mediate the relationship between weight and mental health. Together, these studies provide evidence to support that weight and mental health are both associated with dysregulation of glucocorticoid secretion and metabolism, but that there may be different pathways to depression and obesity. There are other important contributors to/moderators of the development of each phenotype that were not examined in this study, such as early biological programming, gene expression or experience of stress. Further work is required to better understand these pathways and their contributors to both physical and psychological postpartum morbidity.
There are a number of limitations of this study. This was a relatively healthy weight sample with low levels of depression and our conclusions cannot be extrapolated to obese or depressed populations. The absence of expected relationships, such as that between weight change and depression, may be a result of this limitation. Furthermore, the sample was predominantly White, well educated, affluent, with high levels of breastfeeding. There are likely to be important demographic patterns in the relationships between weight retention, depression and cortisol metabolism that this study could not capture. In addition, we did not collect data on stressors such as sleep deprivation, which may have an impact on both mental health and cortisol metabolism 40 . Finally, we did not correct for multiple testing to reduce the risk of a type II error in this small exploratory study, which naturally increases risk of a type I
error. Therefore these findings, whilst important for future hypothesis generation, require replication.
In summary, this study significantly expands our understanding of the relationships between cortisol metabolism, mental health and weight change postpartum. Lower activity of 11β-HSD-1 and 5α-reductase was associated with greater postpartum weight loss in healthy women, independent of demographics and depression. More depressed women also demonstrated higher cortisol secretion rates, independent of demographics and breastfeeding, but depression was unrelated to BMI change. In healthy samples, cortisol metabolism is related to both BMI and symptoms of depression, but weight and depressed mood have independent pathways that link them to HPA activity.
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